23,844 results match your criteria Chronic Lymphocytic Leukemia


Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor T-cell therapy.

Expert Rev Hematol 2019 Feb 22. Epub 2019 Feb 22.

a Division of Medical Oncology, Department of Internal Medicine , University of Washington School of Medicine , Seattle , WA , USA.

Introduction: Chimeric antigen receptor (CAR) T cell immunotherapy has demonstrated remarkable anti-tumor activity in B-cell malignancies and is under investigation in other hematologic malignancies and solid tumors. While highly efficacious, post-infusion T cell activity often results in massive cytokine release precipitating cytokine release syndrome (CRS), the signature toxicity of CAR T cells. This toxicity is characterized by systemic immune activation resulting in fever, hypotension, respiratory insufficiency and capillary leak. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1585238DOI Listing
February 2019

Inheritance of Susceptibility to Malignant Blood Disorders.

Sci Rep 2019 Feb 21;9(1):2444. Epub 2019 Feb 21.

Department of Hematology, Oslo University Hospital, KG Jebsen Center for B cell malignancies P.O. box 4950, Nydalen, NO 0424, Oslo, Norway.

Malignant blood disorders depend on heritable susceptibility genes and occur in familial aggregations. We suggest a model of transgenerational segregation of the susceptibility genes based on the study of malignant blood disorders in Norwegian and Danish families with unrelated parents, and in the inbred Faroese population with related parents. This model, consisting of parental genomic imprinting and mother-son microchimerism, can explain the male predominance in most of the diseases, the predominance of affected parent-offspring when parents are not related, and the different modes of segregation in males and females. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38879-yDOI Listing
February 2019

Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany;

Chronic lymphocytic leukemia cells have an altered energy metabolism compared to normal B cells. While there is growing understanding of the molecular heterogeneity of the disease, the extent of metabolic heterogeneity and its relation to molecular heterogeneity has not been systematically studied. Here, we assessed 11 bioenergetic features, primarily reflecting cell's oxidative phosphorylation and glycolytic activity, in leukemic cells from 140 chronic lymphocytic leukemia patients using metabolic flux analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203067DOI Listing
February 2019

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

University of Virginia School of Medicine, Charlottesville, Virginia, USA.

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targeted cells allows for optimal induction of complement-dependent cytotoxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.207266DOI Listing
February 2019

Immunochemotherapy for Richter syndrome: current insights.

Immunotargets Ther 2019 5;8:1-14. Epub 2019 Feb 5.

Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland,

Richter syndrome (RS) is recognized as the development of a secondary and aggressive lymphoma during the clinical course of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Most of such histological transformations are from RS to diffuse large B-cell lymphoma (DLBCL-RS, 90%) and Hodgkin's lymphoma (HL-RS, 10%). Histopathological examination is a prerequisite for diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/ITT.S167456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368420PMC
February 2019

Engineering extracellular vesicles as novel treatment options: exploiting herpesviral immunity in CLL.

J Extracell Vesicles 2019 11;8(1):1573051. Epub 2019 Feb 11.

Research Unit Gene Vectors, Helmholtz Centre Munich German Research Centre for Environmental Health, Munich, Germany.

Extracellular vesicles (EVs) are important mediators of cell-cell communication. Intriguingly, EVs can be engineered and thus exploited for the targeted transfer of functional proteins of interest. Thus, engineered EVs may constitute attractive tools for the development of novel therapeutic interventions, like cancer immunotherapies, vaccinations or targeted drug delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20013078.2019.1573051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374966PMC
February 2019

Ibrutinib-induced cardiomyopathy.

J Community Hosp Intern Med Perspect 2019 11;9(1):50-52. Epub 2019 Feb 11.

Hematology/Oncology Department, Baylor College of Medicine, Houston, TX, USA.

The use of ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and other hematologic malignancies is blooming. Atrial fibrillation is a known side effect of ibrutinib but cardiomyopathy was not reported previously. We present an 88-year-old man with CLL who was admitted to the hospital with new-onset atrial fibrillation and symptomatic systolic congestive heart failure one month after ibrutinib initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/20009666.2018.1555432DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374917PMC
February 2019

Molecular Players in Hematologic Tumor Cell Trafficking.

Front Immunol 2019 6;10:156. Epub 2019 Feb 6.

Department of Molecular Biomedicine, Centro de Investigaciones Biológicas (CSIC), Madrid, Spain.

The trafficking of neoplastic cells represents a key process that contributes to progression of hematologic malignancies. Diapedesis of neoplastic cells across endothelium and perivascular cells is facilitated by adhesion molecules and chemokines, which act in concert to tightly regulate directional motility. Intravital microscopy provides spatio-temporal views of neoplastic cell trafficking, and is crucial for testing and developing therapies against hematologic cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.00156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372527PMC
February 2019

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

PLoS One 2019 20;14(2):e0211228. Epub 2019 Feb 20.

Serviço de Cardiologia, Hospital Universitário de Santa Maria (CHLN), CAML, Centro Cardiovascular da Universidade de Lisboa-CCUL, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, Portugal.

Introduction: Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia. Ibrutinib has an increased risk of atrial fibrillation but the mechanism is unknown, and hypertension may play a role in the pathogenesis of this adverse drug reaction.

Methods: We aimed to review the risk of hypertension and atrial fibrillation as adverse events associated with ibrutinib through a systematic review with meta-analysis of randomized controlled trials (RCTs) retrieved in December 2018 on MEDLINE, EMBASE, CENTRAL and ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211228PLOS
February 2019
3.234 Impact Factor

Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.

Leuk Res 2019 Jan 24;79:6-16. Epub 2019 Jan 24.

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address:

The BCR-ABL fusion gene (BCR-ABL) has different subtypes such as p210 and p190 with p190 appear to lead to a worse prognosis. To explore the mechanism of difference in pathogenesis and prognosis in different BCR-ABL subtype-related leukemia, expression profile microarray analysis was conducted between p190 and p210 patients and verified by RT-PCR. The p21-activated kinase (PAK1) gene was chosen and regulation of the PAK1-STAT5 biological axis and its influence on proliferation and apoptosis in leukemia cells were also analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2019.01.012DOI Listing
January 2019

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.

Methods Mol Biol 2019 ;1956:199-228

Second Medical Department, University Hospital Schleswig-Holstein, Kiel, Germany.

Minimal residual disease (MRD) diagnostics is of high clinical relevance in patients with indolent B-cell non-Hodgkin lymphomas (B-NHL) and serves as a surrogate parameter to evaluate treatment effectiveness and long-term prognosis. MRD diagnostics performed by real-time quantitative PCR (RQ-PCR) is still the gold standard and currently the most sensitive and the most broadly applied method in follicular lymphoma (FL) and mantle cell lymphoma (MCL). Alternatively, droplet digital PCR (ddPCR) can be used for MRD monitoring in multiple myeloma, mantle cell lymphoma, and follicular lymphoma with comparable sensitivity, accuracy, and reproducibility. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_9DOI Listing
January 2019

Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.

Methods Mol Biol 2019 ;1956:157-197

Division of Internal Medicine, Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany.

The quantification of submicroscopic minimal residual disease (MRD) after therapy proved to have independent prognostic significance in many mature B-cell malignancies. With the advent of routine benchtop cytometers capable of simultaneously analyzing ≥4 colors and with improved standardization, flow cytometry has become the method of choice for MRD assessments in some lymphoma entities. Herein we describe general aspects of flow cytometric standardization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_8DOI Listing
January 2019

Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas.

Methods Mol Biol 2019 ;1956:139-155

Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.

Comprehensive analysis of the clonotypic B cell receptor immunoglobulin (BcR IG) gene rearrangement sequences in patients with mature B cell neoplasms has led to the identification of significant repertoire restrictions, culminating in the discovery of subsets of patients expressing highly similar, stereotyped BcR IG. This finding strongly supports selection by common epitopes or classes of structurally similar epitopes in the ontogeny of these tumors. BcR IG stereotypy was initially described in chronic lymphocytic leukemia (CLL), where the stereotyped fraction of the disease accounts for a remarkable one-third of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_7DOI Listing
January 2019

Expression Cloning of Antibodies from Single Human B Cells.

Methods Mol Biol 2019 ;1956:105-125

Division of B-Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

The majority of lymphomas originate from B cells at the germinal center stage. Preferential selection of B-cell clones by a limited set of antigens has been suggested to drive lymphoma development. While recent studies in chronic lymphocytic leukemia have shown that self-reactive B-cell receptors (BCR) can generate cell-autonomous signaling and proliferation, our knowledge about the role of BCRs for the development or survival of other lymphomas remains limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-9151-8_5DOI Listing
January 2019

Correction to: Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Pharmacoeconomics 2019 Feb 19. Epub 2019 Feb 19.

Warwick Evidence, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry, CV4 7AL, UK.

Open Access This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License ( http://creativecommons.org/licenses/by-nc/4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-019-00773-wDOI Listing
February 2019

Association of SLC28A3 Gene Expression and CYP2B6*6 Allele with the Response to Fludarabine Plus Cyclophosphamide in Chronic Lymphocytic Leukemia Patients.

Pathol Oncol Res 2019 Feb 18. Epub 2019 Feb 18.

Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.

Fludarabine plus cyclophosphamide (FC) chemotherapy is the basis of treatment protocols used in management of chronic lymphocytic leukemia (CLL). In some patients, response to therapy may be affected by aberrant function of genes involved in pharmacokinetics and pharmacodynamics of the drugs. The aim of this research was to assess the impact of pharmacogenetic variability, namely expression of SLC28A3 gene and the presence of CYP2B6*6 variant allele, on the FC treatment efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00613-4DOI Listing
February 2019

Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.

Ann Hematol 2019 Feb 18. Epub 2019 Feb 18.

University of Toulouse III Paul Sabatier, Toulouse, France.

Delivering of > 80% planned relative dose intensity (RDI) of fludarabine-cyclophosphamide-rituximab (FCR) is key to benefit from longer progression free survival (PFS) and survivals in CLL. In this randomized trial, we sought to investigate whether a telephone intervention strategy (called AMA) delivered by an oncology nurse could reduce the risk of RDI < 80% by alleviating adverse events and supporting patients' adherence. Sixty FCR patients were randomized 1:1 for AMA (stratified on Binet stage C). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03631-zDOI Listing
February 2019

Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane.

Nat Commun 2019 Feb 18;10(1):820. Epub 2019 Feb 18.

Institute of Neuro- and Sensory Physiology, University Medical Center Göttingen, Humboldtallee 23, 37073, Göttingen, Germany.

Stimulation of the B cell antigen receptor (BCR) triggers signaling pathways that promote the differentiation of B cells into plasma cells. Despite the pivotal function of BCR in B cell activation, the organization of the BCR on the surface of resting and antigen-activated B cells remains unclear. Here we show, using STED super-resolution microscopy, that IgM-containing BCRs exist predominantly as monomers and dimers in the plasma membrane of resting B cells, but form higher oligomeric clusters upon stimulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-019-08677-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379438PMC
February 2019

DNA methylation profiling implicates exposure to PCBs in the pathogenesis of B-cell chronic lymphocytic leukemia.

Environ Int 2019 Feb 15;126:24-36. Epub 2019 Feb 15.

National Hellenic Research Foundation, Institute of Biology, Medicinal Chemistry and Biotechnology, 48 Vas. Constantinou Ave., Athens 11635, Greece. Electronic address:

Objectives: To characterize the impact of PCB exposure on DNA methylation in peripheral blood leucocytes and to evaluate the corresponding changes in relation to possible health effects, with a focus on B-cell lymphoma.

Methods: We conducted an epigenome-wide association study on 611 adults free of diagnosed disease, living in Italy and Sweden, in whom we also measured plasma concentrations of 6 PCB congeners, DDE and hexachlorobenzene.

Results: We identified 650 CpG sites whose methylation correlates strongly (FDR < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.envint.2019.01.068DOI Listing
February 2019

Paraneoplastic Eosinophilic Dermatosis in a Case of Chronic Lymphocytic Leukemia.

Indian Dermatol Online J 2019 Jan-Feb;10(1):61-63

Department of Skin and VD, SBH Govt. Medical College, Dhule, Department of Skin and VD, Krishna Institute of Medical Sciences, Karad, Maharashtra, India.

Eosinophilic dermatosis of hematologic malignancy is a rare paraneoplastic manifestation particularly associated with chronic lymphocytic leukemia (CLL).Clinically, it presents as a peculiar polymorphic pruritic eruption with characteristic histological findings of superficial and deep dense perivascular infiltrate of lymphocytes and eosinophils without any vasculitis. Although it has been reported intermittently with different names, there is paucity of reports of this condition in Indian literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_121_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362748PMC
February 2019

The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature.

Leuk Lymphoma 2019 Feb 18:1-8. Epub 2019 Feb 18.

a Department of Internal Medicine - Hematology and Oncology , Medical Faculty MU and University Hospital Brno , Brno , Czech Republic.

Cytogenetic examination and the detection of chromosomal aberrations in chronic lymphocytic leukemia (CLL) is an integral part of prognostic stratification and treatment decisions. Improvements in cytogenetic methods, notably the introduction of the cell stimulation method, have led to the detection of chromosomal aberrations in 80% of CLL cases. A comprehensive analysis of cytogenetic aberrations recently showed that complex karyotypes (CKs) defined as the detection of either three or more or five or more chromosomal changes in a karyotype have a poor prognostic impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1576038DOI Listing
February 2019

Evaluating the role of Tregs in the progression of multiple myeloma.

Leuk Lymphoma 2019 Feb 18:1-9. Epub 2019 Feb 18.

c Leukemia/BMT Program of BC, British Columbia Cancer Agency , University of British Columbia , Vancouver , BC , Canada.

The role of regulatory T-cells (Treg) and Th17 cells in the progression of multiple myeloma has been unclear. There are conflicting reports of the Treg and Th17 frequency being increased, decreased, and unchanged as compared with controls. In this study, we sought to characterize the T-cell subsets including Treg function in both blood and marrow compartments of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1579324DOI Listing
February 2019

Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

Crit Rev Oncol Hematol 2019 Feb 19;134:65-70. Epub 2018 Dec 19.

Lady Davis Institute for Medical Research and Segal Cancer Center, Jewish General Hospital, 3755 Cote Ste. Catherine Road, Montreal, Quebec, Canada, H3T 1E2; Department of Oncology, McGill University, Montreal, Quebec, Canada. Electronic address:

Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia in the western world. CLL consists of the accumulation of malignant B-cells in the blood stream and homing tissues. Although treatable, this disease is not curable, and resistance or relapse is often present. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.12.003DOI Listing
February 2019

Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

Br J Haematol 2019 Feb 15. Epub 2019 Feb 15.

Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, UK.

Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi-centre retrospective analysis of 105 R/R CLL patients who received venetoclax pre-National Health Service commissioning. The median age was 67 years and median prior lines was 3 (range: 1-15). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15802
Publisher Site
http://dx.doi.org/10.1111/bjh.15802DOI Listing
February 2019
2 Reads

Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis.

Am J Hematol 2019 Feb 14. Epub 2019 Feb 14.

University of Texas MD Anderson Cancer Center, Houston, TX.

The efficacy of ibrutinib has been demonstrated in patients with chronic lymphocytic leukemia (CLL), including as first-line therapy. However, outcomes after ibrutinib discontinuation have previously been limited to higher-risk populations with relapsed/refractory (R/R) disease. The objective of this study was to evaluate outcomes of ibrutinib-treated patients based on prior lines of therapy, including after ibrutinib discontinuation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25436DOI Listing
February 2019

Chronic lymphocytic leukemia with deletion 17p: An Indian scenario.

South Asian J Cancer 2019 Jan-Mar;8(1):40

Department of Lab Oncology, All India Institute of Medical Sciences, New Delhi, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/sajc.sajc_287_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348775PMC
February 2019

Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?

Turk J Med Sci 2019 Feb 11;49(1):265-271. Epub 2019 Feb 11.

Background/aim: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyte attack. Our goal was to determine the PD-1 and PD-L2 expression rates of various hematologic malignancies, and evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis. Read More

View Article

Download full-text PDF

Source
http://online.journals.tubitak.gov.tr/openAcceptedDocument.h
Publisher Site
http://dx.doi.org/10.3906/sag-1706-194DOI Listing
February 2019
2 Reads

MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest.

Oncogene 2019 Feb 13. Epub 2019 Feb 13.

Department of Molecular Biomedicine, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.

We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces cell arrest. To further explore the latter function, we studied whether MMP-9 influences the gene-expression profile in CLL. Microarray analyses rendered 131 differentially expressed genes in MEC-1 cells stably transfected with MMP-9 (MMP-9-cells) versus cells transfected with empty vector (Mock-cells). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-019-0744-3DOI Listing
February 2019

Low-Dose Fludarabine and Cyclophosphamide Combined With Standard Dose Rituximab (LD-FCR) Is an Effective and Safe Regimen for Elderly Untreated Patients with Chronic Lymphocytic Leukemia: The Israeli CLL Study Group Experience.

Hematol Oncol 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel.

Chronic lymphocytic leukemia (CLL) is a disease of elderly patients. The fludarabine, cyclophosphamide and rituximab (FCR) regimen is considered the treatment of choice for young fit patients with CLL, however, this combination is toxic for older patients. At the time this study was first planned and initiated, there was no standard chemo-immunotherapy regimen regarded as standard therapy for the less fit elderly patient with CLL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2580DOI Listing
February 2019
2 Reads

Not All Strokes Are Strokes An Example of Diagnostic Confirmation Bias.

Eur J Case Rep Intern Med 2019 8;6(1):001006. Epub 2019 Jan 8.

West Middlesex University Hospital, London, United Kingdom.

A 72-year-old woman presented with a complex partial seizure and right hemiparesis, after a four-week history of cognitive decline, apraxia and speech disturbance. She previously had chronic lymphocytic leukaemia (CLL) and had finished chemotherapy one year prior to presentation. She was receiving monthly intravenous immunoglobulins for bronchiectasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12890/2019_001006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372046PMC
January 2019
2 Reads

Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Cureus 2018 Nov 30;10(11):e3660. Epub 2018 Nov 30.

Neurosurgery, Stanford University School of Medicine, Stanford, USA.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia that affects older adults in the Western world. Symptomatic nervous system invasion in undiagnosed CLL is rare, poorly understood, challenging to treat, and associated with decreased survival. The average survival of CLL patients with central nervous system (CNS) involvement is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364951PMC
November 2018
1 Read

Body size and obesity during adulthood, and risk of lympho-hematopoietic cancers: an update of the WCRF-AICR systematic review of published prospective studies.

Ann Oncol 2019 Feb 7. Epub 2019 Feb 7.

Department of Epidemiology and Biostatistics, Imperial College, London, United Kingdom.

Background: To summarise the evidence on the associations between body mass index (BMI) and BMI in early adulthood, height, waist circumference (WC) and waist to hip ratio (WHR), and risk of lympho-hematopoietic cancers.

Method: We conducted a meta-analysis of prospective studies and identified relevant studies published up to December 2017 by searching PubMed. A random effects model was used to calculate dose-response summary relative risks (RRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz045DOI Listing
February 2019
1 Read

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

J Clin Oncol 2019 Feb 11:JCO1800915. Epub 2019 Feb 11.

19 University of Bologna, Bologna, Italy.

Purpose: Indolent non-Hodgkin lymphoma (iNHL) remains largely incurable and often requires multiple lines of treatment after becoming refractory to standard therapies. Duvelisib was approved by the Food and Drug Administration for relapsed or refractory (RR) chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL) and RR follicular lymphoma (FL) after two or more prior systemic therapies. On the basis of the activity of duvelisib, a first-in-class oral dual inhibitor of phosphoinositide 3-kinase-δ,-γ, in RR iNHL in a phase I study, the safety and efficacy of duvelisib monotherapy was evaluated in iNHL refractory to rituximab and either chemotherapy or radioimmunotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00915DOI Listing
February 2019
1 Read

Presence of serum antinuclear antibodies correlating unfavorable overall survival in patients with chronic lymphocytic leukemia.

Chin Med J (Engl) 2019 Feb 6. Epub 2019 Feb 6.

Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.

Background: Serum antinuclear antibodies (ANAs) are positive in some patients with chronic lymphocytic leukemia (CLL), but the prognostic value of ANAs remains unknown. The aim of this study was to evaluate the role of ANAs as a prognostic factor in CLL.

Methods: This study retrospectively analyzed clinical data from 216 newly diagnosed CLL subjects with ANAs test from 2007 to 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CM9.0000000000000114DOI Listing
February 2019
1 Read
1.016 Impact Factor

[Research Advances of Monocyte/Macrophage in Chronic Lymphocytic Leukemia--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2019 Feb;27(1):292-296

Department of Hematology, The Second Affiliated Hospital of Shanxi Medical University, Taiyuan 031001, Shanxi Province, China.E-mail:

Chronic lymphocytic leukemia(CLL)is a malignant hematologic disease with heterogeneous clinical course, about two thirds of patients exhibit a long survival, but the remaining third of patients show aggressiveness of disease or poor response to conventional treatment even drug resistance. Studies suggested that tumor microenvironment possesses a critical effect in CLL disease progression in recent years. Monocyte/macrophage, as an important componens of tumor microenvironment, play a promotive role in the growth and drug reistance of tumor cells by direct cell-to-cell contact, secreting cytokines and suppressing antitumor responses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2019.01.048DOI Listing
February 2019
2 Reads

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.

Int J Cancer 2019 Feb 9. Epub 2019 Feb 9.

Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany.

Despite encouraging results with chimeric antigen receptor T (CART) cells, outcome can still be improved by optimization of the CART cell generation process. The proportion of less-differentiated T cells within the transfused product is linked to enhanced in vivo CART cell expansion and long-term persistence. The clinically approved PI3Kδ inhibitor idelalisib is well established in the treatment of B cell malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32201DOI Listing
February 2019
1 Read

Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.

Blood Adv 2019 Feb;3(3):447-460

Division of Hematology, Department of Internal Medicine, College of Medicine and OSU Comprehensive Cancer Center.

The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib has transformed chronic lymphocytic leukemia (CLL) therapy but requires continuous administration. These factors have spurred interest in combination treatments. Unlike with chemotherapy, CD20-directed antibody therapy has not improved the outcome of BTKi treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018025684DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373734PMC
February 2019

Psoas Abscess Due to in A Patient with Chronic Lymphocytic Leukemia-Case Report and Review.

J Clin Med 2019 Feb 7;8(2). Epub 2019 Feb 7.

University Department of Medicine, Kantonsspital Baselland, University of Basel, 4101 Bruderholz, Switzerland.

Infections may constitute a serious complication in patients with chronic lymphocytic leukemia (CLL). New treatment agents including obinutuzumab and ibrutinib have improved the progression-free survival in CLL, and data suggest a similar overall infection risk and a limited risk of opportunistic infections when compared to standard chemo-immunotherapy. Nevertheless, cases of opportunistic infections including non-tuberculous mycobacterial (NTM) in CLL patients have recently been published. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/jcm8020216DOI Listing
February 2019

A rare pitfall in the molecular interpretation of BRAF V600E status in melanoma in the setting of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma.

J Cutan Pathol 2019 Feb 7. Epub 2019 Feb 7.

Pathology Queensland, Princess Alexandra Hospital Laboratory, Woolloongabba, Queensland, Australia.

BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma. We recently observed a case of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intermixed with BRAF V600E wild-type melanoma reported to harbor BRAF V600E mutation on molecular testing. Our observation underscores the importance of appropriate tumor selection for molecular studies and knowledge of mutational status of co-existing tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13440DOI Listing
February 2019
1 Read

Genomic instability in a chronic lymphocytic leukemia patient with mono-allelic deletion of the and genes.

Mol Cytogenet 2019 31;12. Epub 2019 Jan 31.

2División de Genética, Centro de investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, CIBO-IMSS, Guadalajara, Jalisco Mexico.

Background: The most frequent cytogenetic abnormality detected in chronic lymphocytic leukemia (CLL) patients is the presence of a deletion within the chromosome band 13q14. Deletions can be heterogeneous in size, generally encompassing the and genes (minimal deleted region), but at times also including the gene. The latter, larger type of deletions are associated with worse prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13039-019-0417-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357463PMC
January 2019
1 Read

Risk factors for the development of atrial fibrillation on ibrutinib treatment.

Leuk Lymphoma 2019 Feb 7:1-7. Epub 2019 Feb 7.

c Department of Internal Medicine, Division of Cardiology , Northwestern University Feinberg School of Medicine , Chicago , IL , USA.

Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1533129DOI Listing
February 2019
7 Reads

L-Selectin Expression Is Influenced by Phosphatase Activity in Chronic Lymphocytic Leukemia.

Cytometry B Clin Cytom 2019 Feb 6. Epub 2019 Feb 6.

Faculty of Medicine, Department of Laboratory Medicine, University of Debrecen, Debrecen, Hungary.

Background: Adhesion receptors have important role in cellular invasiveness and L-selectin is a primary determinant in the binding of chronic lymphocytic leukemia (CLL) cells to several glycated proteins on endothelial cells. We investigated L-selectin expression on CLL cells and explored the mechanisms that lead to their shedding.

Methods: Surface and soluble L-selectin expression levels were studied by flow cytometry and immunoassay, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21771DOI Listing
February 2019

Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies.

Transfusion 2019 Feb 6. Epub 2019 Feb 6.

Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington.

Background: The clinical and procedural parameters that affect the optimal collection of lymphocytes for the production of chimeric antigen receptor (CAR) T cells remain undefined but are increasingly important, as commercial products are now available. We evaluated determinants of low lymphocyte collection efficiency (CE) and the rate of successful CAR T-cell manufacture in middle-aged and older adults with advanced B-cell malignancies.

Study Designs And Methods: Mononuclear cell collections using two apheresis platforms (COBE Spectra and Spectra Optia, Terumo BCT) from patients participating in a CD19-directed CAR T-cell therapy trial were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/trf.15178DOI Listing
February 2019
7 Reads

Chronic Lymphocytic Leukemia Presenting as a Subcortical Watershed Infarct.

Case Rep Hematol 2019 9;2019:2089359. Epub 2019 Jan 9.

Internal Medicine, Monmouth Medical Center, Long Branch, New Jersey, USA.

Internal watershed infarcts (WI) involve white matter between deep and superficial arterial systems of middle cerebral artery. These infarcts are considered to be either from low blood flow or microembolism. Anemia is an extremely rare cause of watershed infarcts. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crihem/2019/2089359/
Publisher Site
http://dx.doi.org/10.1155/2019/2089359DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343168PMC
January 2019
3 Reads

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia.

SAGE Open Med Case Rep 2019 16;7:2050313X18823917. Epub 2019 Jan 16.

Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL, USA.

Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously. We introduced obinutuzumab for the retreatment in a chronic lymphocytic leukemia patient, who had first achieved partial remission with it and eventually relapsed over a course of 2. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/2050313X18823917
Publisher Site
http://dx.doi.org/10.1177/2050313X18823917DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350017PMC
January 2019
3 Reads